Global Carcinoid Syndrome Diarrhea Treatment Market Overview
Analysis of carcinoid syndrome diarrhea is grounded on manifestations of diarrhea and flushing joined with target discoveries of carcinoid tumor through biopsy, multiphase stomach/pelvic MRI, CT, or biomarkers. Looseness of the bowels happens in 80% of patients with carcinoid syndrome. Encounter of watery, unstable, loose stools numerous times in a day is regular in patients with carcinoid syndrome diarrhea, which can be troublesome for the patient and defying for the healthcare provider. One unit study by U.S pharmacists found that medicinal services costs are 1.5-crease higher and the danger of hospitalization is two-overlap higher in patients with carcinoid syndrome diarrhea than in those without diarrhea. The pathophysiology of carcinoid syndrome diarrhea includes the presence of overabundance serotonin, which fortifies secretion of colonic mucus, augments peristalsis, and restrains absorption in the gastrointestinal tract- all of which prompts diarrhea. In contrasted with sound patients, proximal-colon travel time might be up to six times speedier and small-bowel travel time might be twice as quick in patients with carcinoid syndrome diarrhea.
Market Size & Forecast
Carcinoid Syndrome Diarrhea Treatment Market is anticipated to record a significant CAGR over the forecast period i.e. 2018-2027. On March 1, 2017 FDA approved Lexicon Pharmaceuticals, Inc. of orally administered therapy drug Xermelo for the treatment of carcinoid syndrome diarrhea. Since the treatment offered for carcinoid syndrome diarrhea are limited, multiple companies are focusing on increased research and development for new targeted delivery of disease thus targeting huge market share in carcinoid syndrome diarrhea treatment market.Carcinoid syndrome diarrhea is described by indications such as abdominal discomfort, fatigue, facial flushing, and might direct to damage in the heart valve. If carcinoid syndrome diarrhea goes untreated it may lead to excessive electrolyte imbalance, weight loss, dehydration, and other life-threatening symptoms. Thus, the growing awareness regarding these symptoms amongst the population is expected to increase the carcinoid syndrome diarrhea treatment market across the globe.On the basis of regional platform, global carcinoid syndrome diarrhea treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
North America is predicted to be the most dominant region in terms of revenue generation for the carcinoid syndrome diarrhea treatment market. Regulatory approval and better reimbursement policies are expected to be factor driving the growth. The high prevalence of carcinoid syndrome diarrhea in the U.S is estimated to drive the market in this region. The market in Europe is as well anticipated to grow significantly owing to the regulatory body facilitation in the development and authorization of orphan drugs.Asia Pacific especially is expected to be a lucrative market and show significant growth over the forecast period as cases of carcinoid syndrome diarrhea are increasing in this region as well as due to increase in research and development activities, and ongoing development of healthcare infrastructure in this region.
Our-in depth analysis of the global Carcinoid Syndrome Diarrhea Treatment market includes the following segments:
- Oral Therapy
- Chemo Therapy
- Somatostatin Analog Therapy
By End-User Industries
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Global Carcinoid Syndrome Diarrhea Treatment Market is further classified on the basis of region as follows:
- North America (United States, Canada), Market size, Y-O-Y growth Market size, Y-O-Y growth & Opportunity Analysis, Future forecast & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
Growth Drivers & Challenges
Carcinoid syndrome diarrhea is a rare condition. Treatment available for this condition is expected to get orphan drug status. Regulatory bodies and governments support for development of orphan drugs and incentives that are estimated to propel the carcinoid syndrome treatment market. Government allows companies to set high price for the orphan drug which in turn will generate high revenue. Carcinoid syndrome diarrhea treatment market would grow during the forecast years as many multi-national companies are focusing towards new product innovations in carcinoid syndrome diarrhea treatment. Furthermore, due to the limited available treatment process for this disease, the carcinoid syndrome diarrhea treatment market would experience a lift, and the company's manufacturing drugs would target an extensive market hence gaining huge market share in the carcinoid syndrome diarrhea treatment. Other aspects influencing the carcinoid syndrome diarrhea treatment market are increasing incidences of hormonal disorders and growing smoking habits.However, the carcinoid syndrome diarrhea treatment market may be restrained over the forecast period due to lower adoption of carcinoid syndrome diarrhea treatment in developing nations and the low availability of therapeutic options for treatment of this disease.
Top Featured Companies Dominating The Market
- Lexicon Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis International AG (Sandoz)
- Pharmascience Inc.
- Teva Pharmaceutical Industries Ltd.
- Omega Laboratories Ltd.
- Ipsen Biopharmaceuticals, Inc.
- Mylan N.V.
- Sirtex Medical Limited
- BTG International Ltd.
- Wockhardt Ltd.